BioCentury
ARTICLE | Clinical News

M-ONC 402: Phase I/II started

July 9, 2012 7:00 AM UTC

Momenta began a 2-part, open-label, U.S. Phase I/II trial to evaluate daily oral M402 in combination with gemcitabine in about 150 patients. The first part will evaluate multiple ascending-doses of M4...